UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 16, 2016

DELMAR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-54801	99-0360497			
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)			
	Suite 720-999 West Broadway				
	Vancouver, British Columbia				
	Canada V5Z 1K5				
((Address of principal executive offices) (zip code)				
	(604) 629-5989				
(1	Registrant's telephone number, including area code)				
	Copies to:				
	Gregory Sichenzia, Esq.				
	Jeff Cahlon, Esq.				
	Sichenzia Ross Friedman Ference LLP				
	61 Broadway				
	New York, New York 10006				
	Phone: (212) 930-9700				
	Fax: (212) 930-9725				
(Former address, if changed since last report)					
Check the appropriate box below if the Form any of the following provisions (see General	8-K filing is intended to simultaneously satisfy the Instruction A.2. below):	filing obligation of the registrant under			
☐ Written communications pursuant to Rule	425 under the Securities Act (17 CFR 230.425)				
	2 under the Exchange Act (17 CFR 240.14a-12)				
	uant to Rule 14d-2(b) under the Exchange Act (17 C				
☐ Pre-commencement communications pursu	uant to Rule 13e-4(c) under the Exchange Act (17 C	CFR 240.13e-4(c))			

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

On May 16, 2016, the Company filed a Certificate of Change with the Secretary of State of Nevada. Pursuant to the Certificate of Change, the Company effected a four-for-one reverse split (the "Reverse Split") of its outstanding common stock, and the number of authorized shares of common stock was correspondingly reduced from 200,000,000 to 50,000,000. The Reverse Split became effective in the market at the open of business on May 20, 2016.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

3.1 Certificate of Change filed with the Nevada Secretary of State on May 16, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 20, 2016

DELMAR PHARMACEUTICALS, INC.


By: /s/ Jeffrey Bacha

Name: Jeffrey Bacha Title: Chief Executive Officer



BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-6708 Website: www.nvsos.gov





Barbara K. Cegavske Secretary of State State of Nevada

20160220402-79

Filing Date and Time

05/16/2016 1:54 PM

Entity Number

E0341392009-0

Certificate	of C	hange	Pursuant
to	NRS	78.20	9

USE BLACK INK ONLY - DO NOT HIGHLIGHT	ana filad i	ABOVE SPACE IS FOR OFFI	CE USE ONLY
		Pursuant to NRS 78.209 Corporations	
Name of corporation:	add i Tolli	OOI POTALIONS	
DelMar Pharmaceuticals, Inc.			
The board of directors have adopted a reserve required approval of the stockholders.	olution purs	suant to NRS 78.209 and have obtained a	ny
The current number of authorized shares a shares before the change:		value, if any, of each class or series, if an	y, of
200,000,000 shares of common stock, par value 5,000,000 shares of preferred stock, par value			:
4. The number of authorized shares and the the change:	oar value, i	f any, of each class or series, if any, of sha	ares after
50,000,000 shares of common stock, par value 5,000,000 shares of preferred stock, par value			
5. The number of shares of each affected class for each issued share of the same class or se	ss or series	, if any, to be issued after the change in e	xchange
Every 4 shares of issued and outstanding comnewly issued stock.	mon stock	shall be surrendered and exchanged for 1 s	share of
The provisions, if any, for the issuance of for scrip to stockholders otherwise entitled to a fr affected thereby:	actional shaction of a	ares, or for the payment of money or the i share and the percentage of outstanding	ssuance of
Fractional shares to be rounded up.			
7. Effective date and time of filing: (optional)	Date:	Time:	:
8. Signature: (required)	(mu	st not be later than 90 days after the certificate is fil	ed)
X CANACO		_ Chief Executive Officee	1
Signature of Off/cer (Title	
IMPORTANT: Failure to include any of the above info	motion and	submit with the proper feet may cause this filling to	he rejected

This form must be accompanied by appropriate fees.

Nevada Secretary of State Stock Split Revised: 1-5-15